Journal article
Molecular predictors of gemcitabine response in pancreatic cancer
World journal of gastrointestinal oncology, Vol.3(11), pp.153-164
11/15/2011
DOI: 10.4251/wjgo.v3.i11.153
PMCID: PMC3220724
PMID: 22110842
Abstract
Gemcitabine is one of the most used anti-neoplastic drugs with documented activity in almost all major localizations of cancer. In pancreatic cancer treatment, gemcitabine occupies a prominent place as a first line chemotherapy, partly because of the paucity of other efficacious chemotherapy options. In fact, only a minority of pancreatic cancer patients display a response or even stability of disease with the drug. There are currently no clinically applicable means of predicting which patient will derive a clinical benefit from gemcitabine although several proposed markers have been studied. These markers are proteins involved in drug up-take, activation and catabolism or proteins that define the ability of the cell to undergo apoptosis in response to the drug. Several of these markers are reviewed in this paper. We also briefly discuss the possible role of stem cells in drug resistance to gemcitabine. (C) 2011 Baishideng. All rights reserved.
Details
- Title: Subtitle
- Molecular predictors of gemcitabine response in pancreatic cancer
- Creators
- Ioannis A. Voutsadakis - Charmo University
- Resource Type
- Journal article
- Publication Details
- World journal of gastrointestinal oncology, Vol.3(11), pp.153-164
- DOI
- 10.4251/wjgo.v3.i11.153
- PMID
- 22110842
- PMCID
- PMC3220724
- NLM abbreviation
- World J Gastrointest Oncol
- ISSN
- 1948-5204
- eISSN
- 1948-5204
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 12
- Language
- English
- Date published
- 11/15/2011
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984808088502771
Metrics
3 Record Views